Target expression details
Target General Information | |||||
---|---|---|---|---|---|
Target ID | T22095 | ||||
Target Name | Interleukin-17 | ||||
Synonyms | CTLA-8; Cytotoxic T lymphocyte-associated antigen 8; IL-17; IL-17A; IL17A | ||||
Target Type | Successful | ||||
Gene Name | IL17B | ||||
Biochemical Class | Cytokine: interleukin | ||||
UniProt ID | IL17B_HUMAN||IL17C_HUMAN||IL17D_HUMAN||IL17F_HUMAN||IL17_HUMAN||IL25_HUMAN | ||||
Target Gene Expression Profiles in the Disease-Relevant Drug Targeted Tissue of the Patients and Healthy Individuals | |||||
Disease | Rheumatoid arthritis | ||||
Example drug | ABT-122 | Phase 2 | [525076], [889413], [1572592] | ||
Tissue | Synovial tissue | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: -0.16 Z-score: -0.69 P-value: 2.91E-02 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
Target Gene Expression Profiles in Other Tissues of Healthy Individuals | |||||
Reference | |||||
Ref 525076 | ClinicalTrials.gov (NCT02349451) A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis Who Have an Inadequate Response to Methotrexate. U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.